Aug 4, 2026 04:05PM
Jun 23, 2026 08:00AM
Jun 23, 2026 08:00AM
May 5, 2026 04:01PM
Apr 2, 2026 12:00PM
Apr 2, 2026 10:46AM
Apr 2, 2026 08:31AM FDA accepts Ultragenyx resubmission for rare disease gene therapy UX111
Apr 2, 2026 08:30AM
Mar 30, 2026 08:32AM
Mar 30, 2026 08:30AM
Feb 23, 2026 08:30AM
Feb 23, 2026 08:30AM
Feb 18, 2026 06:44AM
Feb 12, 2026 04:01PM Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
Feb 3, 2026 06:44AM
Jan 30, 2026 08:31AM
Jan 30, 2026 08:30AM
Jan 12, 2026 07:31AM
Jan 12, 2026 07:30AM
Dec 30, 2025 04:06PM
Dec 30, 2025 04:05PM Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
Dec 30, 2025 04:58AM
Dec 30, 2025 02:03AM
Dec 29, 2025 01:50PM
Dec 29, 2025 08:30AM
Dec 29, 2025 08:30AM
Nov 4, 2025 04:05PM
Oct 30, 2025 08:00AM Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups
Sep 8, 2025 04:05PM
Sep 8, 2025 04:05PM
Aug 18, 2025 08:06AM
Aug 18, 2025 08:00AM
Aug 5, 2025 04:01PM
Jul 31, 2025 04:05PM
Jul 31, 2025 04:05PM Ultragenyx Completes Enrollment of Phase 3 Aspire Study Evaluating GTX-102 for the Treatment of Angelman Syndrome
Jul 14, 2025 08:01AM
Jul 14, 2025 08:00AM
Jul 11, 2025 05:05PM
Jul 11, 2025 04:30PM
Jul 11, 2025 04:30PM
Jul 9, 2025 04:05PM
Jul 9, 2025 04:05PM Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis
Jun 27, 2025 08:00AM
Jun 27, 2025 08:00AM
May 6, 2025 04:01PM
Feb 19, 2025 07:13AM
Feb 18, 2025 08:07AM
Feb 18, 2025 08:00AM
Feb 13, 2025 04:01PM Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
Feb 5, 2025 08:00AM

328,350 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All